ReachRxResearch
Home
Research
Sign Up
Ring and community vaccination for Bundibugyo virus outbreak response: a stochastic network modelling study
Back to Research Hub
  1. Home
  2. Research Hub
  3. Ring and community vaccination for Bundi…

Ring and community vaccination for Bundibugyo virus outbreak response: a stochastic network modelling study

The Lancet Infectious Diseases·September 2
Infectious DiseasesPractice changingBundibugyo Virus DiseaseEbola Virus DiseaseStochastic Network Modelling StudyLive Attenuated Recombinant VaccineMixedErveboRVSV-ZEBOV

Summary

View source

What was studied

This stochastic network modelling study evaluated the population impact and dose efficiency of a partially cross-protective hypothetical vaccine (45% effectiveness) against Bundibugyo virus (BDBV) during a 2026 DR Congo outbreak, comparing base operations, enhanced case-finding/tracing, reactive ring vaccination (Ring 1 & 2), and community vaccination at 20–80% coverage over 90 days.

Key findings

Enhanced operations alone (70% detection, 80% tracing) reduced expected mortality by 81.6% (95% UI 73.1–87.7%). Adding Ring 2 vaccination to enhanced operations gave only an incremental 10.5% (6.2–15.6%) further mortality reduction; community vaccination at 80% coverage reduced mortality by 86.6% (79.2–90.4%) but required 53.8–111.4 doses per death averted, vs. 35.1 doses per death averted for Ring 2.

Study limitations

The vaccine effectiveness of 45% is hypothetical — no licensed BDBV-specific vaccine exists and true cross-protection from rVSV-ZEBOV is unproven. The model is calibrated to one ongoing outbreak and results may not generalize to other BDBV settings or outbreak sizes. Operational constraints (e.g., cold chain, community acceptance) are approximated rather than empirically validated.

Clinical implications

Prioritize rapid case detection, isolation, and contact tracing first — these alone can avert most BDBV deaths even with a partially effective vaccine. If a cross-protective vaccine becomes available, ring vaccination is dose-efficient, but broad community vaccination will be needed to achieve the largest outbreak impact.

Caveats

  • Sample size tag reflects simulation replicates (10,000 per strategy), not enrolled human participants — this is a modelling study with no patient-level data.
  • The 'practice_changing' impact flag is applied cautiously: findings are simulation-based and contingent on a vaccine that does not yet exist, but the operational conclusions regarding case-finding primacy are directly actionable.
  • The vaccine effectiveness value (45%) is hypothetical — no empirically validated BDBV-specific vaccine exists; real-world cross-protection from rVSV-ZEBOV against BDBV is unproven.

Related Questions

Explore related topics

What is the evidence for rVSV-ZEBOV cross-protection against non-Ebola filoviruses like Bundibugyo?How effective is contact tracing and ring vaccination in controlling filovirus outbreaks in Central Africa?What are the dose efficiency trade-offs between ring and community vaccination strategies for emerging viral hemorrhagic fevers?

Publication Details

Year
2026
Journal
The Lancet Infectious Diseases
Sample Size
n=10,000
Source
View article
Keep scrolling
More content below.
Up Next